fruquintinib + FOLFIRI

Fruquintinib + FOLFIRI is a combination regimen used in the treatment of metastatic colorectal cancer (mCRC). Fruquintinib is a novel, highly selective small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1/2/3), thereby inhibiting angiogenesis and tumor blood vessel maturation. It is approved for use in adults with metastatic colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy as well as anti-VEGF therapy. FOLFIRI is a standard chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. The combination of fruquintinib with FOLFIRI has shown promising clinical benefit as second-line or later therapy for patients with RAS-mutant mCRC, achieving high disease control rates and manageable safety profiles in ongoing clinical trials[2][8][5].